Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	127
Overall Study	STARTED	Astegolimab (MSTT1041A) 70mg	127
Overall Study	STARTED	Astegolimab (MSTT1041A) 210mg	126
Overall Study	STARTED	Astegolimab (MSTT1041A) 490mg	122
Overall Study	COMPLETED	Placebo	121
Overall Study	COMPLETED	Astegolimab (MSTT1041A) 70mg	117
Overall Study	COMPLETED	Astegolimab (MSTT1041A) 210mg	117
Overall Study	COMPLETED	Astegolimab (MSTT1041A) 490mg	113
Overall Study	NOT COMPLETED	Placebo	6
Overall Study	NOT COMPLETED	Astegolimab (MSTT1041A) 70mg	10
Overall Study	NOT COMPLETED	Astegolimab (MSTT1041A) 210mg	9
Overall Study	NOT COMPLETED	Astegolimab (MSTT1041A) 490mg	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02918019/flow